Physician profile
Sandra I Walker
NPI 1952664179
$7,566.18
in general payments reported to CMS, 2019-2025
34 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,137 · 2022: $1,415 · 2023: $1,774 · 2024: $2,046 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,014.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,590.35 | 2021-2025 | |
| Novo Nordisk INC | $1,472.16 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $616.29 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $495.61 | 2021-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $413.65 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $394.16 | 2021-2024 | Spravato |
| Biohaven Pharmaceutical Holding Company LTD. | $272.11 | 2022 | |
| Glaxosmithkline, LLC. | $227.59 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Axsome Therapeutics, INC. | $219.49 | 2023-2025 | Auvelity, Symbravo |
| Merck Sharp & Dohme LLC | $178.71 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Phathom Pharmaceuticals, INC. | $160.79 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $155.14 | 2021-2024 | Trintellix |
| Astellas Pharma US INC | $150.41 | 2021-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $145.12 | 2023-2025 | Cologuard Collection Kit |
| Optinose US, INC. | $124.92 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.94 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $109.52 | 2021-2024 | Farxiga, Airsupra |
| Azurity Pharmaceuticals, INC. | $93.21 | 2024-2025 | Edarbi, Horizant |
| Bayer Healthcare Pharmaceuticals INC. | $90.64 | 2022 | |
| Lundbeck LLC | $74.20 | 2022-2025 | Vyepti |
| Kowa Pharmaceuticals America, INC. | $69.64 | 2021-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $64.07 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $56.14 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Biohaven Pharmaceuticals, INC. | $49.95 | 2021 | |
| Amarin Pharma, INC. | $43.16 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $41.57 | 2021-2022 | |
| Dexcom, INC. | $28.96 | 2023 | Dexcom G6 Transmitter |
| Endo Pharmaceuticals INC. | $25.94 | 2021 | |
| Nevro Corp. | $24.46 | 2024 | Senza |
| Eisai INC. | $16.53 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.85 | 2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $11.84 | 2021 | |
| Dynavax Technologies Corporation | $10.56 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.